Comparative observation between Roxithromycin and Azithromycin sequential therapy in the treatment of Mycoplasma pneumoniae Pneumonia in Children

Dan Liu; Yi-fei Zhang

doi:10.12669/pjms.40.9.8942

Author(s)

Dan Liu Department of Neonatology, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei, China. The First Clinical Medical Collage of Yangtze University, Jingzhou 434000, Hubei, China.

Yi-fei Zhang Department of Pediatric Medicine, Chief Physician, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei, China.

Abstract

Objective: To investigate the clinical eficacy of roxithromycin combined with azithromycin sequential therapy in the treatment of mycoplasma pneumoniae pneumonia in children. Methods: A retrospective study was conducted on 100 patients with mycoplasma pneumoniae pneumonia admitted to The First Afiliated Hospital of Yangtze University from January 2020 to December 2022. All patients were divided into the observation group (roxithromycin combined with azithromycin sequential therapy) and the control group (azithromycin sequential therapy), with 50 cases in each group. The clinical eficacy, improvement time of clinical symptoms/signs, inflammation indexes, oxidative stress indexes and immune function levels of the two groups were compared. Moreover, the improvement of lung function indexes and the adverse reactions were observed. Results: The overall response rate of the observation group was 96.00%, which was higher than the control group (84.00%) (p<0.05). The time of clinical symptoms/signs in the observation group were significantly lower than those in the control group(p<0.05). After treatment, significant improvements were seen in the levels of CRP, TNF-a, IL-6, GSH-Px, SOD, MDA, CD3+, CD4+, CD4+/CD8+, IgM, IgG , IgA, FEV1, FEV1%, FVC and FEV1/FVC of the two groups compared with those before treatment (p<0.05), and the improvement in the observation group was more obvious than that in the control group (p<0.05). The overall incidence of adverse reactions in the observation group was 6.00%, which was slightly lower than that in the control group (8.00%) (c²=0.154, P=0.695). Conclusion: Roxithromycin combined with azithromycin sequential therapy is a safe regimen for the treatment of mycoplasma pneumoniae pneumonia in children.

Publication Details

Page(s) 2124-2129

DOI 10.12669/pjms.40.9.8942

Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 9, Year: 2024

Request the full text from PASTIC

Keywords

Sequential therapy, Children, Azithromycin, Children, Mycoplasma pneumoniae pneumonia, clinical eficacy, Roxithromycin

References

Zhang J,Wang T,Li R,Ji W,Yan Y,Sun Z .2021 .Prediction of risk factors of bronchial mucus plugs in children with Mycoplasma pneumoniae pneumoniae pneumonia. BMC Infect Dis, 10(1) : 67.

Shi DW,Wang DM,Ning LH,Li J,Dong Y,Zhang ZK .2022 .Using 16S rDNA Sequencing Technology to Preliminarily Analyze Intestinal Flora in Children with Mycoplasma pneumoniae pneumoniae Pneumonia. Biomed Environ Sci, 10(6) : 528-537.

Cook S,Conway RJH,Pinto-Sander N,Soni S. .2019 .Delayed clearance of Mycoplasma genitalium following azithromycin treatment. -054064, 10(5) : 392.

Sun LL,Ye C,Zhou YL,Zuo SR,Deng ZZ,Wang CJ .2020 .Metaanalysis of the Clinical Efficacy and Safety of High- and Low-dose Methylprednisolone in the Treatment of Children With Severe Mycoplasma pneumoniae pneumoniae Pneumonia. Pediatr Infect Dis J, 10(3) : 177-183.

Yuan X,Liu J,Bai C,Niu W,Wang J,Li P .2020 .Tigecycline in the treatment of fulminant Mycoplasma pneumoniae pneumoniae pneumonia non-responsive to azithromycin and fluoroquinolone: A case report. Medicine (Baltimore), 10(28) : .

Bi Y,Zhu Y,Ma X,Xu J,Guo Y,Huang T .2021 .Development of a scale for early prediction of refractory Mycoplasma pneumoniae pneumoniae pneumonia in hospitalized children. Sci Rep, 10(1) : 6595.

.2021 .Pulmonary and Extrapulmonary Manifestations in Hospitalized Children with Mycoplasma Pneumoniae Infection. Microorganisms, 10(12) : 2553.

Desai S,Hall M,Lipsett SC,Shah SS,Brogan TV,Hersh AL .2021 .Mycoplasma pneumoniae pneumoniae Testing and Treatment Among Children with Community-Acquired Pneumonia. Hosp Pediatr, 10(7) : 005215-763.

Jin X,Zhu Y,Zhang Y,Chen J,Rong L,Zhao X .2018 .Assessment of levels of D-dimer and interferon-γ in pediatric patients with Mycoplasma pneumoniae pneumoniae pneumonia and its clinical implication. Exp Ther Med, 10(6) : 5025-5030.

Qu J,Chen S,Bao F,Gu L,Cao B .2019 .Molecular characterization and analysis of Mycoplasma pneumoniae pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China. Int J Infect Dis, 03 : 26-31.

Zhang C,Zhang Q,Du JL,Deng D,Gao YL,Wang CL .2020 .Correlation Between the Clinical Severity, Bacterial Load, and Inflammatory Reaction in Children with Mycoplasma pneumoniae pneumoniae Pneumonia. Curr Med Sci, 10(5) : 822-828.

Guo Z,Liu L,Gong J,Han N,He L,Wang W .2022 .Molecular features and antimicrobial susceptibility of Mycoplasma pneumoniae pneumoniae isolates from paediatric inpatients in Weihai, China: Characteristics of M. pneumoniae In Weihai. J Glob Antimicrob Resist, 01 : 180-184.

Jin HL,Zhan L,Mei SF,Shao ZY .2020 .Serum Cytokines and FeNO in School-Aged Children with Mycoplasma pneumoniae pneumoniae Pneumonia. Med Sci Monit, 10 : .

Diaz MH,Benitez AJ,Cross KE,Hicks LA,Kutty P,Bramley AM .2015 .Molecular Detection and Characterization of Mycoplasma pneumoniae pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States. Open Forum Infect Dis, 10(3) : .

Eckerle M,Mvalo T,Smith AG .2022 .Identifying modifiable risk factors for mortality in children aged 1-59 months admitted with WHO-defined severe pneumonia: a single-centre observational cohort study from rural Malawi. doi: 10.1007/s13312-012-0221-3, 6(1) : .

Wagner K,Imkamp F,Pires VP,Keller PM .2018 .Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolideresistant Mycoplasma pneumoniae pneumoniae in pneumonia patients. Clin Microbiol Infect, 10(3) : e5-383.

Zheng JL,He LL .2018 .The clinical efficacy of sequential therapy of azithromycin combined with erythromycin in the treatment of pediatric mycoplasma pneumonia. J Clin Rational Drug Use, 13(33) : 1389-59.

Jiang N. .2021 .The effect of sequential treatment with azithromycin on serum CRP in children with Mycoplasma pneumoniae pneumonia Analysis of the Impact of G-CSF Level. Chinese Pract Med, 06(6) : 5547-18.

Zhang H,Li X,Wang J,Cheng Q,Wang GZ .2021 .Baicalin relieves mycoplasma pneumoniae pneumoniae infection induced lung injury through regulating microRNA221 to inhibit the TLR4/NFKB signaling pathway. Mol Med Rep, 10(2) : 571.

Kutty PK,Jain S,Taylor TH,Bramley AM,Diaz MH,Ampofo K .2019 .Mycoplasma pneumoniae pneumoniae Among Children Hospitalized With Community-acquired Pneumonia. Clin Infect Dis, 10(1) : 5-12.

Ha SG,Oh KJ,Ko KP,Sun YH,Ryoo E,Tchah H .2018 .Levofloxacin against MacrolideUnresponsive Mycoplasma pneumoniae pneumoniae Pneumonia in Children. J Korean Med Sci, 33(43) : .